Navigation Links
Poster & Abstract Entitled 1H-MRS & FDG-PET Studies in the SOD1 G93A - the Use of Stabilized Peptides as a Rationale for Future Treatment in ALS Presented During Annual Northeast ALS Consortium Meeting

CLEARWATER, Florida, October 30, 2013 /PRNewswire/ --

Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, presented a poster at the 12th Annual Meeting of the North East ALS (NEALS) Consortium which took place 3rd-4th October 2013, at the Sandpearl Resort, Clearwater Beach, FL, USA. The poster was entitled "1H-MRS & FDG-PET studies in the SOD1 G93A - the use of stabilized peptides as a rationale for future treatment in ALS" and was co-authored by scientists and researchers from Daval and Charles River Discovery Research Services, Finland.

The North East ALS Consortium is an alliance of medical institutions that are equipped to perform clinical trials in Amyotrophic Lateral Sclerosis (ALS) and motor neuron diseases. The Annual NEALS Meeting serves as an opportunity for NEALS researchers to liaise with leading ALS and motor neuron disease scientists, government sponsors, academic partners and pharmaceutical companies in order to discuss potential treatments, to review current research activities and to share scientific updates.  

The objectives of the studies were to determine whether targeting of the hypothalmo-pituitary-adrenal axis at a specific site using AIMSPRO®, the novel multi-protein-peptide conjugate complex, currently in clinical development, could elicit multiple measurable efficacy traits in the G93A SOD1 murine model. The SOD-1 model is the most studied ALS mouse model and the results showed clinical efficacy, associated changes in brainstem 1H-MRS metabolites and appeared to target glutamate/glutamine availability and in a separate study rescued the G93A SOD1 brain from hypometabolism.

Professor Syed Haq, Daval's Chief Clinical & Scientific Officer and one of the co-authors, presented the poster in Florida and commented, "These results are extremely encouraging and supportive of other studies that have been undertaken pre-clinically as well as in double-blind, placebo-controlled clinical trials in humans. The Implications and findings has led to further work to elucidate the potential targets in ALS that may have future therapeutic implications in the treatment of patients diagnosed with ALS where glutamate exocitotoxicity and hypometabolism of the brain have been defined as potential pathogenic mechanisms in the evolution of the disease".

The poster will be available for download at the Daval International website shortly, as soon as the organisers permission has been obtained.

Notes to Editors


AIMSPRO® is a proprietary, purified, protein-multi-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of neurological and autoimmune diseases where regulation and stabilisation of the immune system is required. The therapeutic has a unique mechanism of action that supports its broad potential application in neuro-degenerative diseases. AIMSPRO has been granted a Specials License by the UK's MHRA and has been granted Orphan Drug Designation for ALS by the Food & Drug Administration (FDA) in the United States.

About Daval International Limited

DAVAL INTERNATIONAL LIMITED is an emerging life sciences company focused on the development and delivery of novel and distinctive treatments for serious unmet medical needs through a combination of innovation, dedication, entrepreneurship, skilled science and partnership. From its inception in 2000, the founder and management team of Daval have had a vision of bringing effective treatments that noticeably improves the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.

For further information please contact:

Edward Jensen +1-484-716-9305 or +44(0)7775-793513

Graham Ralph  +44-(0)845-130-3014

SOURCE Daval International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
2. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
3. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
4. MedImmune To Present Seven Posters On Influenza, Respiratory Syncytial Virus At The Annual Pediatric Academic Societies Meeting
5. Data Related to Chimerixs Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
6. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
9. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
10. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
11. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):